Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prospective follow-up study of golimumab in ankylosing spondylitis
NL-OMON41382Phase 4Recruiting
- Sponsor
- Jan van Breemen Institute
- Start
- Mar 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of golimumab in ankylosing spondylitis (AS), sponsored by Jan van Breemen Institute. Primary endpoints: ASAS20 response, ASDAS improvement and 1 more. Started Mar 2012; status: recruiting.
02
Drugs
golimumab
03
Conditions
ankylosing spondylitis (AS)
Beyond the preview
Go deeper on NL-OMON41382.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON41382.